Children with pathogenic variants in BMPR2 or ACVRL1, with or without HHT, have poor clinical outcomes by comparison to noncarriers, typically experiencing a marked limitation of physical activity (WHO functional class III) within 3 years of diagnosis, highlighting the need for rapid mutation detection and treatment 6, 10. This evidence concerns the gene BMPR2 and hereditary hemorrhagic telangiectasia.